Related Experiment Video
Updated: Dec 18, 2025
08:46
A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells
Published on: November 12, 2019
53.9K
CD47: the next checkpoint target for cancer immunotherapy
Ridong Feng1, Hai Zhao1, Jianguo Xu1
1Department of Neurosurgery, West China Hospital, Sichuan University, Chengdu, Sichuan, 610041, China.
Critical Reviews in Oncology/Hematology
|June 15, 2020
Summary
CD47 is a novel immune checkpoint target for cancer immunotherapy. Blocking CD47 shows promise in treating advanced cancers, offering new hope for patients unresponsive to current treatments.
Area of Science:
- Immunology
- Oncology
- Molecular Biology
Background:
- Cancer immunotherapy, particularly checkpoint blockade, has revolutionized advanced cancer treatment.
- Limited patient response necessitates exploring alternative immune checkpoints.
- CD47, a 'marker-of-self' protein overexpressed in many tumors, is a promising macrophage immune checkpoint.
Purpose of the Study:
- To review the structure, physiological functions, and cancer biology implications of CD47.
- To discuss the therapeutic potential of CD47 blockade in cancer immunotherapy.
- To explore future directions and challenges for CD47 as a therapeutic target.
Main Methods:
- Literature review of CD47 structure, function, and role in cancer.
- Analysis of recent clinical findings, including CD47 blockade (Hu5F9-G4) combined with Rituximab in non-Hodgkin's lymphoma.
Main Results:
- CD47 blockade demonstrates potential as a potent immunotherapy strategy.
- Combination therapy with CD47 blockade and Rituximab shows promise in specific hematologic malignancies.
Conclusions:
- CD47 represents a significant emerging target for cancer immunotherapy.
- Further research and development are crucial to overcome challenges and realize the widespread therapeutic use of CD47 blockade.
Related Concept Videos
01:27Tumor Immunotherapy
1.6K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.6K
02:57Targeted Cancer Therapies
8.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.5K
01:30Cancer Vaccines
867
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
867